Show simple item record

dc.contributor.authorO'Brien, Stephen G
dc.contributor.authorVieira, Sara A D
dc.contributor.authorConnors, Samantha
dc.contributor.authorBown, Nick
dc.contributor.authorChang, James
dc.contributor.authorCapdeville, Renaud
dc.contributor.authorMelo, Junia V
dc.date.accessioned2009-09-07T16:18:51Z
dc.date.available2009-09-07T16:18:51Z
dc.date.issued2002-05-01
dc.identifier.citationTransient response to imatinib mesylate (STI571) in a patient with the ETV6-ABL t(9;12) translocation. 2002, 99 (9):3465-7 Blooden
dc.identifier.issn0006-4971
dc.identifier.pmid11964320
dc.identifier.urihttp://hdl.handle.net/10541/80173
dc.description.abstractWe report the transient response of a patient with the ETV6-ABL fusion gene to imatinib mesylate (STI571). A 38-year-old man was referred with an erroneous diagnosis of Philadelphia-positive chronic myeloid leukemia in blastic transformation for treatment with the ABL tyrosine kinase inhibitor, STI571. Further investigation indicated that the patient in fact had acute myeloid leukemia; no evidence of the Philadelphia translocation or BCR-ABL was found using fluorescence in situ hybridization (FISH) or reverse transcription-polymerase chain reaction. Detailed FISH analysis identified a cryptic t(9;12) translocation, and molecular studies confirmed the presence of the ETV6-ABL fusion transcript. Because the patient was gravely ill at presentation, treatment was commenced immediately with STI571 monotherapy, resulting in considerable initial improvement. However within 10 days the patient's condition again deteriorated, and he required conventional chemotherapy. This case has implications for the design of future studies using STI571 in leukemias involving ABL-encoded fusion proteins other than BCR-ABL.
dc.language.isoenen
dc.subjectMyeloid Leukaemiaen
dc.subject.meshAcute Disease
dc.subject.meshAdult
dc.subject.meshChromosomes, Human, Pair 12
dc.subject.meshChromosomes, Human, Pair 9
dc.subject.meshDNA-Binding Proteins
dc.subject.meshGenes, abl
dc.subject.meshHumans
dc.subject.meshLeukemia, Myeloid
dc.subject.meshMale
dc.subject.meshOncogene Proteins, Fusion
dc.subject.meshPiperazines
dc.subject.meshProto-Oncogene Proteins c-ets
dc.subject.meshPyrimidines
dc.subject.meshRecurrence
dc.subject.meshRepressor Proteins
dc.subject.meshTranslocation, Genetic
dc.titleTransient response to imatinib mesylate (STI571) in a patient with the ETV6-ABL t(9;12) translocation.en
dc.typeArticleen
dc.contributor.departmentSchool of Clinical and Laboratory Sciences and the School of Biochemistry and Genetics, University of Newcastle, United Kingdom. s.g.o'brien@ncl.ac.uken
dc.identifier.journalBlooden
html.description.abstractWe report the transient response of a patient with the ETV6-ABL fusion gene to imatinib mesylate (STI571). A 38-year-old man was referred with an erroneous diagnosis of Philadelphia-positive chronic myeloid leukemia in blastic transformation for treatment with the ABL tyrosine kinase inhibitor, STI571. Further investigation indicated that the patient in fact had acute myeloid leukemia; no evidence of the Philadelphia translocation or BCR-ABL was found using fluorescence in situ hybridization (FISH) or reverse transcription-polymerase chain reaction. Detailed FISH analysis identified a cryptic t(9;12) translocation, and molecular studies confirmed the presence of the ETV6-ABL fusion transcript. Because the patient was gravely ill at presentation, treatment was commenced immediately with STI571 monotherapy, resulting in considerable initial improvement. However within 10 days the patient's condition again deteriorated, and he required conventional chemotherapy. This case has implications for the design of future studies using STI571 in leukemias involving ABL-encoded fusion proteins other than BCR-ABL.


This item appears in the following Collection(s)

Show simple item record